The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer

Cancer 2026

View at publisher
Authors: Shetal A. Patel, Jonathan L. Heald, Michael A. Nead, Bart Singer, George A. Eapen, Farhood Farjah, Karen Kelly, Edward S. Kim, Haresh Mani, Raymond U. Osarogiagbon, Nicholas J. Pastis, Jasleen Kaur Pannu
+10 more Lynette Scholl, Catherine R. Sears, Gerard A. Silvestri, Robert A. Smith, Robert D. Suh, Douglas Wood, Terri A. DiJulio, Bruce E. Johnson, Ignacio Ivan Wistuba, M. Patricia Rivera
DOI: 10.1002/cncr.70384
Cited by: 1
References: 18

Abstract

Molecular profiling has revolutionized the diagnosis and management of patients with non-small cell lung cancer (NSCLC), enabling personalized treatment approaches that have significantly improved patient outcomes. Identifying specific gene mutations and protein expression profiles guides therapeutic decisions and has become standard in the management of patients with NSCLC. Multiple organizations have published guidelines for biomarker testing. However, differences in the timing, methodology, and scope of recommended targets create potential for inconsistencies in clinical practice. This article reviews the clinical importance of biomarker testing in NSCLC, compares major guidelines, and highlights the challenges and implications of guideline variability in formulating recommendations on biomarker testing for patients with NSCLC.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies

Publication details

Journal / source
Cancer
Publisher
Wiley
Volume
132
Issue
10
Pages
e70384–e70384
Publication date
12 May 2026
Language
EN